Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1830 - Adherence to International ESO-ESMO (ABC) guide-lines in HER2-ve metastatic breast cancer (MBC) patients (pts) – Preliminary results of the GIM 13 - AMBRA Study

Date

11 Sep 2017

Session

Poster display session

Presenters

Marina Cazzaniga

Citation

Annals of Oncology (2017) 28 (suppl_5): v74-v108. 10.1093/annonc/mdx365

Authors

M. Cazzaniga1, G. Mustacchi2, M. Giordano3, O. Garrone4, M. Donadio5, L. del mastro6, L. Livi7, C. Natoli8, A. Michelotti9, A. Turletti10, R. Ferdinando11, M. De Laurentiis12, P. Marchetti13, M. Montemurro14, E. Romagnoli15, S. De Placido16, P. Pronzato17, L. Biganzoli18, G. Bisagni19, E. Bria20

Author affiliations

  • 1 Medical Oncology, Osp San Gerardo, 20900 - Monza/IT
  • 2 Oncology, University of Trieste-Ospedale di Cattinara, 34149 - Trieste/IT
  • 3 Oncology, Presidio Ospedaliero Ospedale Sant'Anna, 22100 - San Fermo della Battaglia/IT
  • 4 Medical Oncology, Azienda Ospedaliera St. Croce e Carle, 12100 - Cuneo/IT
  • 5 Medical Oncology, AOU S. Giovanni Battista - Molinette, 10126 - Torino/IT
  • 6 Medical Oncology, AO San Martino IST, genova/IT
  • 7 Radioterapia, Azienda Ospedaliera Universitaria Careggi, Florence/IT
  • 8 Medical Oncology, P.O. Clinicizzato Ss. Annunziata Universita' Degli Studi, 66100 - Chieti/IT
  • 9 Medical Oncology, Azienda Ospedaliera Universitaria S.Chiara, 56100 - Pisa/IT
  • 10 Medical Oncology, AOU S. Giovanni Battista - Molinette, torino/IT
  • 11 Medical Oncology, AO Cardarelli, Napoli/IT
  • 12 Medical Oncology, IRCCS Fondazione Pascale, Napoli/IT
  • 13 Medical Oncology, Azienda Ospedaliera St. Andrea, 00189 - Roma/IT
  • 14 Medical Oncology, Ist Candiolo, Torino/IT
  • 15 Medical Oncology, Ospedale Generale Provinciale Macerata, 62100 - Macerata/IT
  • 16 Medical Oncology, Università degli studi di Napoli "Federico II"-Dipartimento di Medicina Clinica e Chirurgia – Oncologia, Napoli/IT
  • 17 Medical Oncology, IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, 16132 - Genova/IT
  • 18 Medical Oncology, Ospedale di Prato Sandro Pitigliani Med. Oncology Unit, 59100 - Prato/IT
  • 19 Medical Oncology, Azienda Ospedaliera Arcispedale Santa Maria Nuova - IRCCS, 42100 - Reggio Emilia/IT
  • 20 Medical Oncology, Ospedale Universitario Verona, 37129 - Verona/IT
More

Resources

Abstract 1830

Background

ESO/ESMO develops consensus guidelines for MBC treatment every 2 years, potentially applicable worldwide. Aim of the present analysis is to verify the adherence to ABC recommendations for HER2-ve MBC in the context of the AMBRA study.

Methods

AMBRA is a longitudinal cohort study, aiming to describe the choice of first and subsequent lines of treatment in HER2-ve MBC pts receiving at least one Chemotherapy (CHT) (SABCS 2016, P5-15-07 & P5-14-09). For the present analysis, we selected 4 statements from the ABC1 & ABC2 Conferences, comparing them with the clinical choices of 1st-line therapy in all evaluable cases.

Results

So far, 791 pts have been enrolled, of whom 586 (74.1%) have received CHT as 1st-line treatment. 479 pts (81.7%) had Luminal tumours at diagnosis. First-line CHT was monotherapy in 89 pts (25.2%), anthra-based CHT in 45 (7.7%) and platinum-based in 38 (6.5%), mainly TNBC (20/38, 52.6%). Selected recommendations and percentages of adherence are reported in Table.Table:

259P Adherence to ABC recommendations for HER2-ve pts

n/N (%of adherence)
1 - Anthracycline (A)- or Taxane (T)-based regimens, preferably as a single agent, would usually be considered as first-line CHT, in those pts who have not received these regimens as adjuvant treatmentA/T mono 59/ 270 (21.8%)160/270 (59.2%)
A/T poly 101/ 270 37.4%)
2 - In pts with taxane-naive and anthracycline-resistant MBC, taxane-based therapy, preferably as a single agent, would usually be considered as the treatment of choiceT mono 89/ 431 (20.6%)208/431 (48.2%)
T poly 119/ 431 (27.6%)
3 - Other options are Capecitabine and Vinorelbine135/586 (23.0%)
4 - If given in the adjuvant setting, a taxane can be re-used in the metastatic setting, particularly if there has been at least 1 year of disease-free survivalDFI > 12 months 74/79 (93.7%)79/151 (52.3%)
DFI

Conclusions

The adherence to clinical recommendations is very low, being only partially applied in all the clinical situations analyzed. Educational interventions are urgently needed and a confrontation with the clinical community is strongly recommended.

Clinical trial identification

Legal entity responsible for the study

Marina E. Cazzaniga

Funding

Celgene Intl.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.